1044771-76-7

Basic information

• Product Name: (4-Chloro-pyrimidin-2-yl)-cyclopropyl-amine
• Synonyms: 4-Chloro-N-cyclopropyl-2-pyrimidinamine;(4-Chloro-pyrimidin-2-yl)-cyclopropyl-amine;4-Chloro-N-cycloproimidin-2-amine
• CAS NO: 1044771-76-7
• Molecular Formula: C7H8ClN3
• Molecular Weight: 170
• Mol File: 1044771-76-7.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Density: 1.454
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (4-Chloro-pyrimidin-2-yl)-cyclopropyl-amine(CAS DataBase Reference)
• NIST Chemistry Reference: (4-Chloro-pyrimidin-2-yl)-cyclopropyl-amine(1044771-76-7)
• EPA Substance Registry System: (4-Chloro-pyrimidin-2-yl)-cyclopropyl-amine(1044771-76-7)

Safety Data

• Hazardous Substances Data: 1044771-76-7(Hazardous Substances Data)

Usage

General Description

(4-Chloro-pyrimidin-2-yl)-cyclopropyl-amine is a chemical compound with the molecular formula C7H8ClN3. It is a cyclopropylamine derivative with a chloro-pyrimidine group attached to the cyclopropyl ring. (4-Chloro-pyrimidin-2-yl)-cyclopropyl-amine is used in the pharmaceutical industry for the synthesis of various drugs and pharmaceuticals. It is also used as a building block in organic synthesis to create a variety of compounds. The presence of the chloro and pyrimidine groups in the molecule gives it potential for various biological activities, making it a valuable tool in drug discovery and development. Additionally, it is important to handle this chemical with care and caution due to its potential hazardous properties.

Upstream product

• 3934-20-1 2,6-Dichloropyrimidine 
• 765-30-0 Cyclopropylamine 

Relevant articles and documents

Pyrimidinyl Biphenylureas: Identification of New Lead Compounds as Allosteric Modulators of the Cannabinoid Receptor CB1

The allosteric modulator 1-(4-chlorophenyl)-3-(3-(6-(pyrrolidin-1-yl)pyridin-2-yl)phenyl)urea (PSNCBAM-1, 2) bound the cannabinoid receptor 1 (CB1) and antagonized G protein coupling. This compound demonstrated potent anorectic effects similar to the CB1 antagonist rimonabant that once was marketed for the treatment of obesity, suggesting a new chemical entity for the discovery of antiobesity drugs. To increase structural diversity of this class of CB1 ligands, we designed and synthesized two classes of novel analogues, in which the pyridine ring of 2 was replaced by a pyrimidine ring. These positively modulate the binding of the CB1 orthosteric agonist CP55,940 while exhibiting an antagonism of G-protein coupling activity. Interestingly, compounds 7d and 8d demonstrated ERK1/2 phosphorylation mediated via β-arrestin unlike the orthosteric CP55,940 that does so in a G protein-dependent manner. These can serve as new lead compounds for the future development of CB1 allosteric modulators that show biased agonism and potentially antiobesity behavior via a new mechanism.